Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant interferon gamma therapy for atopic dermatitis

J M Hanifin1, L C Schneider, D Y Leung

  • 1Department of Dermatology, Oregon Health Sciences University, Portland 97201-3098.

Journal of the American Academy of Dermatology
|February 1, 1993
PubMed
Summary

Recombinant interferon-gamma (rIFN-gamma) effectively treated severe atopic dermatitis in a 12-week study. Patients receiving rIFN-gamma showed significant symptom improvement and reduced inflammation, with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.

The Journal of dermatological treatment·2020
Same author

Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

7-5 by '05.

Archives of dermatology·2014
Same author

Assessment of comparative skills between hand-assisted and straight laparoscopic colorectal training on an augmented reality simulator.

Diseases of the colon and rectum·2010
Same author

Advanced applications of 3-dimensional echocardiography.

Minerva cardioangiologica·2009

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis involves immunologic abnormalities, including reduced interferon gamma production.
  • Current treatments for atopic dermatitis are limited and often unsatisfactory.
  • Prior studies suggested recombinant interferon-gamma (rIFN-gamma) may be effective for severe atopic dermatitis.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant human interferon gamma therapy in patients with atopic dermatitis.
  • To conduct a randomized, placebo-controlled, double-blind, multicenter study on rIFN-gamma treatment.
  • To assess clinical, immunologic, and laboratory safety parameters.

Main Methods:

  • 83 patients with moderate to severe atopic dermatitis received daily subcutaneous injections of 50 micrograms/m2 rIFN-gamma (n=40) or placebo (n=43) for 12 weeks.

Related Experiment Videos

  • Clinical severity, body surface area involvement, and laboratory parameters were monitored.
  • Physician and patient overall response evaluations were recorded.

    • Main Results:

    • 45% of rIFN-gamma patients showed >50% improvement vs. 21% for placebo (p=0.016) based on physician evaluation.
    • Patient-reported outcomes also showed significant improvement in the rIFN-gamma group (53% vs. 21%, p=0.002).
    • Significant reductions in erythema, excoriations, and conjunctivitis were observed with rIFN-gamma; eosinophil counts were significantly reduced (p=0.003).

    Conclusions:

    • Recombinant interferon-gamma (rIFN-gamma) is safe, well-accepted, and effective for severe atopic dermatitis.
    • Daily subcutaneous rIFN-gamma over 12 weeks reduced inflammation, clinical symptoms, and eosinophilia.
    • Side effects were generally manageable, with some patients requiring dose adjustments.